http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-097591-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3037c8e592fd4614ee12864f3070efbb |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2440-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91205 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4425 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate | 2014-09-08^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1213e4c520315668fe0b22c42415c17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_324ea7a2b9b11829fd9b83674d143ff4 |
| publicationDate | 2016-03-23^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-097591-A1 |
| titleOfInvention | METHODS TO DETERMINE THE THERAPY RESPONSE |
| abstract | Claim 1: A method for evaluating the effectiveness of a metadoxine treatment regimen in a subject who has Fragile X Syndrome or another cognitive disorder that has received a metadoxine treatment, comprising: a) measuring the amount of ERK proteins and Akt phosphorylated in a sample derived from the subject; b) measure the total amount of ERK and Akt proteins in the sample; c) calculate a relationship between the amount of phosphorylated ERK and Akt proteins determined in step (a) and the amount of ERK and Akt proteins determined in step b); and d) comparing the calculated relationship of stage c) with a calculated ratio measured from a subject without disease, where if the calculated ratio of stage c) is similar to the calculated ratio of the subject without disease, this indicates that the Treatment is effective. Claim 5: The method according to any one of the preceding claims, wherein the measurement steps comprise an immunoassay. Claim 6: The method according to any one of the preceding claims, wherein the sample is whole blood or a fraction thereof. Claim 7: The method according to any one of the preceding claims, wherein the sample is a peripheral blood mononuclear cell (PBMC). |
| priorityDate | 2013-09-09^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 27 of 27.